&nbsp;

jonathanFoster.jpg

Jul 2021

Regimen

VEMU+RITU

Cancer Type:

Hematologic,

Leukemia - Hairy Cell

Intent: Palliative

Drugs Used:

vemURAFenib (Unfunded),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2022

Regimen

VEMU

Cancer Type:

Hematologic,

Leukemia - Hairy Cell

Intent: Palliative

Drugs Used:

vemURAFenib (Unfunded)

Quick Link(s):

Regimen Monograph

Document

view-print-pcir-01.png

Dec 1969

Document

view-print-pcir-02.png

Dec 1969

Document

Vaginal-Vault-Testing-FAQs.pdf

Dec 1969

Vaginal Vault Testing

Document

January-2025-Colposcopy-CoP.pdf

Dec 1969

Regimen

VORA

Cancer Type:

Central Nervous System

Intent: Curative, Palliative

Drugs Used:

vorasidenib (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

VENE+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Updated

Sep 2025

Regimen

VENE+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia

Exceptional Access Program

venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria

Drugs Used:

oBINutuzumab,

venetoclax